Bora Pharmaceuticals News and Resources

Bora Biologics, a growing division of contract development and manufacturing organisation (CDMO) Bora Pharmaceuticals, has announced its collaboration with DotBio, a Singaporean biopharmaceutical company. Bora will assist in the development and manufacturing of DotBio’s lead asset, DB007, a tri-specific antibody

Bora Pharmaceuticals Co., Ltd., a global contract development and manufacturing organization (CDMO), has announced the grand opening of its new small molecule dose form manufacturing facility in Zhongli, Taiwan. This expansion marks a significant step in enhancing Bora’s ability to

Bora Pharmaceuticals Co., Ltd. has announced its acquisition of U.S.-based Pyros Pharmaceuticals, Inc., a specialty pharmaceutical company focused on rare disease treatments. Pyros, founded in 2017, recently launched VIGAFYDE, the first ready-to-use vigabatrin oral solution for infantile spasms (IS) in

Bora Pharmaceuticals Co. Ltd. has completed the acquisition of Emergent BioSolutions’ sterile manufacturing facility located in Baltimore-Camden, Maryland. This acquisition expands Bora’s capabilities in drug product manufacturing, particularly in the area of sterile injectables, adding to its existing biologics drug

Bora Pharmaceuticals Co., Ltd. announced the acquisition of Emergent BioSolutions’ sterile manufacturing facility in Baltimore-Camden, Maryland. This move marks a significant step in Bora’s commercial expansion strategy in North America. Earlier this year, Bora acquired Upsher-Smith Laboratories, a generics manufacturer